Recombinant Human Histamine H4 receptor (HRH4)

What is the tissue expression profile of HRH4 in humans?

HRH4 displays a distinctive expression pattern predominantly in immune cells and hematopoietic tissues. It is mainly expressed in bone marrow with restricted expression in immune cells including monocytes, macrophages, dendritic cells, and T cells. Beyond immune cells, HRH4 expression has been detected in multiple organs including the liver, colon, lung, spleen, small intestine, testes, tonsils, thymus, and trachea. Within the central nervous system, HRH4 has been identified in the cerebellum and hippocampus . Importantly, HRH4 expression can be dynamically regulated in lymphoid tissues, with either upregulation or downregulation observed upon activation, potentially influenced by specific cytokines such as IL-10 and IL-13 .

The expression profile in specific cell types is particularly relevant as it aligns with HRH4's immunomodulatory functions. For instance, HRH4 expression in macrophages increases under high glucose conditions (25 mM) compared to normal glucose (5 mM) conditions, suggesting a potential role in metabolic inflammatory diseases . In testicular tissue, HRH4 has been detected in Leydig cells from rats aged 7-240 days, with additional expression noted in male gametes within seminiferous tubules of 21-day-old rats .

How does HRH4 differ structurally from other histamine receptors?

HRH4 exhibits distinct structural characteristics that differentiate it from other histamine receptor subtypes:

HRH4 is structurally unique compared to the classical pro-inflammatory H1 receptor and the H2 receptor, showing little sequence homology with these subtypes. Interestingly, HRH4 shows approximately 35% homology with the H3 receptor, making H3 its closest related histamine receptor subtype . This structural distinction is reflected in their evolutionary origins, as H3 and H4 receptors appear more closely related to peptide ligand GPCRs than to other biogenic amine receptors including H1 and H2 .

The receptor is a 7-transmembrane G-protein-coupled receptor with a total length of 390 amino acids in humans. The protein sequence contains specific domains critical for ligand binding and signal transduction that contribute to its unique pharmacological profile .

What are the primary signaling pathways associated with HRH4 activation?

HRH4 activation initiates several distinct signaling cascades that mediate its biological effects:

• G-protein-mediated signaling: Upon histamine binding, HRH4 primarily couples to Gi/o proteins, leading to inhibition of adenylyl cyclase and subsequent reduction in intracellular cAMP levels. This mechanism has been demonstrated in steroidogenic cells, where HRH4 agonists inhibit LH/hCG-induced cAMP production .

• Calcium mobilization: HRH4 activation triggers intracellular Ca2+ mobilization in several cell types, particularly in murine mast cells, which contributes to cellular responses without affecting degranulation .

• Chemotactic signaling: A critical pathway involves the βγ subunit of G-proteins acting on phospholipase C to cause actin polymerization, ultimately leading to chemotaxis of immune cells. This mechanism is particularly important for mast cell and eosinophil recruitment in inflammatory settings .

• MAPK pathway modulation: Evidence suggests HRH4 can influence MAP kinase signaling, affecting cell proliferation and differentiation processes. In Leydig tumor cells, HRH4 agonists inhibit cell proliferation, suggesting involvement in growth regulatory pathways .

• Cytokine production regulation: HRH4 signaling modulates the production of inflammatory mediators, including IL-6 and VEGF, which has implications for conditions like diabetic retinopathy .

These signaling pathways collectively contribute to HRH4's role in immune cell chemotaxis, inflammatory responses, and tissue-specific functions such as steroidogenesis in testicular cells.

What are optimal cellular models for studying recombinant HRH4?

Several experimental models have proven valuable for investigating HRH4 function:

Bone marrow-derived macrophages (BMDMs) represent an excellent primary cell model for studying HRH4 function in immune cells. These cells upregulate HRH4 expression when exposed to high glucose (25 mM) for 48 hours, making them particularly useful for investigating HRH4's role in metabolic inflammatory conditions . The macrophage model allows for assessment of chemotaxis, cytokine production, and receptor regulation under various inflammatory stimuli.

MA-10 Leydig tumor cells have been used effectively to study HRH4's role in steroidogenesis and cell proliferation. These cells express functional HRH4 that can be detected by immunofluorescence techniques and respond to HRH4 agonists with inhibition of LH/hCG-induced steroidogenic activity . Primary cultures of progenitor and immature rat Leydig cells provide complementary non-tumoral models that have demonstrated susceptibility to the anti-proliferative effects of HRH4 agonists .

For high-throughput pharmacological studies, recombinant expression systems using HEK293 or CHO cells transfected with human HRH4 enable detailed characterization of receptor-ligand interactions, though these systems may lack the full complement of physiologically relevant signaling components.

What methodologies are effective for measuring HRH4 activity?

Researchers can employ several complementary techniques to assess HRH4 activity:

• Chemotaxis assays: Migration assays using Boyden chambers or transwell systems provide functional readouts of HRH4 activation in immune cells. For example, histamine-induced chemotaxis of macrophages can be measured and the specific contribution of HRH4 confirmed using selective antagonists like JNJ7777120 (JNJ) .

• cAMP determination: Since HRH4 couples to Gi/o proteins, measuring the inhibition of adenylyl cyclase activity provides a direct assessment of receptor activation. Techniques include radioimmunoassays for cAMP or reporter gene assays with cAMP-responsive elements .

• Calcium mobilization: Fluorescent calcium indicators can detect intracellular calcium flux following HRH4 activation, particularly in mast cells and other immune cells .

• Protein expression analysis: Western blotting for downstream signaling molecules like StAR protein has been used to evaluate HRH4's impact on steroidogenesis in Leydig cells .

• Proliferation assays: [3H]-thymidine incorporation assays have successfully demonstrated the antiproliferative effects of HRH4 agonists on both tumoral and normal Leydig cells .

• Gene expression studies: RT-PCR and RNA sequencing can detect changes in HRH4 expression under different conditions, such as the upregulation observed in macrophages exposed to high glucose .

For confirming specificity, parallel experiments with selective HRH4 antagonists are essential, as is the inclusion of appropriate controls for other histamine receptor subtypes.

What are the most selective pharmacological tools for studying HRH4?

Several compounds have emerged as valuable tools for investigating HRH4 function:

JNJ7777120 (JNJ) represents one of the most valuable pharmacological tools as a highly selective HRH4 antagonist with minimal cross-reactivity to other histamine receptors . This compound effectively blocks histamine-induced chemotaxis in macrophages and has demonstrated therapeutic potential in various disease models, including diabetic retinopathy. Its relatively short half-life should be considered when designing experimental protocols, often necessitating daily administration in in vivo studies.

VUF 8430 has been employed as a selective HRH4 agonist in studies examining the receptor's role in testicular function, where it was shown to inhibit steroidogenesis and proliferation in Leydig cells . When designing experiments with these compounds, researchers should include appropriate controls to confirm specificity, such as testing effects in HRH4-knockout models or in cells where the receptor has been silenced via RNA interference.

For comprehensive pharmacological characterization, concentration-response studies are essential, as is consideration of potential species differences in receptor pharmacology, which may complicate translation between animal models and human applications.

How does HRH4 modulate macrophage function in inflammatory conditions?

HRH4 plays a critical role in regulating macrophage behavior during inflammatory conditions, particularly in metabolic diseases such as diabetic retinopathy (DR):

• Glucose-dependent regulation: High glucose environments (25 mM) significantly upregulate HRH4 expression in bone marrow-derived macrophages compared to normal glucose conditions (5 mM), suggesting a specific link between metabolic stress and HRH4 function .

• Chemotactic mechanism: HRH4 mediates histamine-induced macrophage chemotaxis, particularly in cells exposed to high glucose. This chemotactic response can be effectively blocked by selective HRH4 antagonists like JNJ7777120, indicating a direct role for HRH4 in immune cell recruitment to inflammatory sites .

• Inflammatory mediator production: Macrophages expressing HRH4 secrete inflammatory cytokines and growth factors, including IL-6 and VEGF, which contribute to vascular pathology in conditions like diabetic retinopathy .

• Tissue infiltration control: In a streptozotocin-induced diabetic retinopathy mouse model, administration of JNJ7777120 reduced macrophage infiltration into retinal tissue, subsequently decreasing inflammatory responses and vascular permeability .

The experimental evidence strongly suggests that targeting HRH4 could modulate macrophage-driven inflammation. In diabetic retinopathy studies, HRH4 appears to be highly expressed in retinal macrophages but not in T cells, suggesting cell-type specificity that could be exploited therapeutically . This selective expression pattern offers the potential for targeted interventions that might minimize off-target effects on other immune cell populations.

What is the role of HRH4 in steroidogenesis and cell proliferation?

Research on testicular cells has revealed unexpected functions of HRH4 beyond the immune system:

• Steroidogenic regulation: Functional HRH4 expression has been demonstrated in MA-10 Leydig tumor cells, where receptor activation inhibits LH/hCG-induced cAMP production and StAR protein expression, key components of the steroidogenic pathway .

• Antiproliferative effects: HRH4 agonist treatment inhibits proliferation in both MA-10 Leydig tumor cells and normal progenitor and immature rat Leydig cells, suggesting a conserved growth regulatory function across normal and tumoral contexts .

• Developmental expression pattern: Immunohistochemical studies have detected HRH4 in Leydig cells from rats of various ages (7-240 days), indicating potential roles throughout testicular development. Additionally, 21-day-old rats showed HRH4 expression within seminiferous tubules in male gametes, suggesting functions in germ cell development or maturation .

These findings reveal unexpected sites of functional HRH4 expression with potential implications for reproductive physiology and pathology. The dual effects on steroidogenesis and proliferation suggest HRH4 may serve as an endogenous regulator of testicular function, potentially responding to local histamine production within the reproductive tract.

This research highlights important considerations for the development of HRH4-targeted therapeutics, as systemic administration of HRH4 agonists might have unintended consequences on steroid hormone production or reproductive cell proliferation that should be carefully evaluated during drug development .

How do HRH4 polymorphisms influence disease susceptibility?

Genetic variations in the HRH4 gene have been associated with disease susceptibility, particularly in inflammatory conditions:

• Asthma endophenotypes: Several single nucleotide polymorphisms (SNPs) in the HRH4 gene have shown significant associations with specific asthma characteristics, particularly infection-induced asthma .

• Key polymorphisms: Three specific HRH4 SNPs have demonstrated significant associations with infection-induced asthma:

  • rs17187619: p = 0.002; odds ratio (OR) = 2.4 (95% CI: 4.1-1.4)

  • rs527790: p = 0.0002; OR = 3.3 (95% CI: 6.1-1.8)

  • rs487202: p = 0.00007; OR = 3.5 (95% CI: 6.6-1.9)

• Haplotype associations: Specific haplotypes containing the rs4800573-rs527790 CC allele combination were found to be associated with infection-induced asthma (p = 0.0009, OR = 0.5, 95% CI: 0.4-0.8). Additionally, the rs487202-rs574913 CA haplotype was more frequent among patients with infection-induced asthma (p = 0.0006, OR = 1.9, 95% CI: 1.3-2.6) .

• Functional implications: While these genetic associations have been established, research is still needed to determine the functional consequences of these polymorphisms on receptor expression, binding affinity, or signaling efficiency.

These findings suggest that genetic variation in HRH4 may contribute to individual differences in inflammatory disease susceptibility and potentially treatment response. For researchers, these polymorphisms may serve as important variables to consider when designing clinical studies or interpreting heterogeneous responses to HRH4-targeted therapeutics. Future studies should aim to characterize the functional impact of these genetic variants on receptor biology and explore potential genotype-guided therapeutic approaches.

What are the current limitations in HRH4-targeted therapeutics?

Despite promising preclinical results, several challenges remain in developing effective HRH4-targeted therapeutics:

• Pharmacokinetic limitations: Current HRH4 antagonists like JNJ7777120 have relatively short half-lives, necessitating frequent dosing regimens. In animal studies, this has influenced administration protocols, with daily dosing required for sustained effects .

• Selective targeting challenges: While HRH4 appears predominantly expressed on immune cells, its expression in other tissues (such as testicular cells) raises concerns about potential off-target effects of systemic HRH4 modulators .

• Interspecies differences: There are notable variations in HRH4 pharmacology between species, which complicate the translation of preclinical findings to human applications. These differences need to be carefully addressed and taken into consideration during drug development .

• Genetic polymorphisms: The influence of HRH4 genetic variants on receptor function and therapeutic response represents an additional layer of complexity. Individual variations in receptor genetics may affect drug efficacy and require personalized therapeutic approaches .

• Limited clinical validation: Despite extensive preclinical evidence supporting HRH4 as a therapeutic target, human clinical validation remains limited for many proposed indications, necessitating further translational research.

Addressing these challenges will require multifaceted approaches, including the development of new HRH4 modulators with improved pharmacokinetic properties, targeted delivery systems to minimize off-target effects, and increased attention to the role of genetic variation in determining therapeutic outcomes.

How might HRH4 antagonism be applied in diabetic retinopathy?

Research on HRH4's role in diabetic retinopathy (DR) has revealed promising therapeutic applications:

These findings suggest development pathways for HRH4 antagonists as oral medications for preventative treatment of diabetic retinopathy, potentially benefiting diabetes patients before retinal complications manifest. Future research should focus on optimizing dosing regimens, exploring sustained-release formulations, and conducting longer-term studies to determine the durability of protective effects.

What novel methodological approaches are enhancing HRH4 research?

Emerging methodologies are advancing our understanding of HRH4 biology and therapeutic potential:

• Structural biology approaches: Recent advances in determining the three-dimensional structure of HRH4 and its ligand binding sites are providing crucial insights for rational drug design. These structural studies enable more precise development of selective agonists and antagonists .

• Genetic engineering techniques: CRISPR/Cas9 gene editing allows for precise manipulation of HRH4 sequences, facilitating the study of specific polymorphisms and their functional consequences. This approach enables the creation of cellular and animal models with human-relevant HRH4 variants.

• Single-cell analysis: Application of single-cell RNA sequencing and proteomics to immune cell populations is revealing unprecedented detail about HRH4 expression patterns in specific cell subsets and disease states, moving beyond the limitations of bulk tissue analysis.

• In vivo imaging: Development of PET tracers and other molecular imaging approaches specific for HRH4 offers the potential to visualize receptor distribution and occupancy in living subjects, bridging the gap between in vitro pharmacology and clinical effects.

• Computational modeling: Machine learning and artificial intelligence approaches are being applied to predict HRH4-ligand interactions, optimize drug candidates, and identify patterns in genetic association data that may not be apparent through conventional statistical analysis.

These methodological advances collectively promise to accelerate progress in understanding HRH4 biology and developing targeted therapeutics. Integration of structural insights with functional and genetic data provides a more comprehensive foundation for translational research in this field.

What are the implications of HRH4 in non-allergic inflammatory conditions?

Beyond its established roles in allergic inflammation, HRH4 demonstrates significant involvement in various non-allergic inflammatory conditions:

• Autoimmune diseases: Evidence suggests HRH4 participates in the pathogenesis of autoimmune disorders through modulation of dendritic cell function and T cell differentiation. HRH4 influences dendritic cell activation and CD4+ T cell responses, potentially contributing to dysregulated immune responses in conditions like rheumatoid arthritis .

• Chronic pruritus: HRH4 has emerged as a promising target for treating chronic itching conditions that may be resistant to traditional antihistamines targeting H1 receptors. The distinct signaling pathways of HRH4 may offer therapeutic advantages in these challenging clinical scenarios .

• Diabetic complications: Recent research has established HRH4's role in diabetic retinopathy through regulation of macrophage infiltration and inflammatory mediator production. This suggests potential involvement in other diabetes-related complications characterized by chronic inflammation .

• Neuroimmune interactions: HRH4 expression in specific brain regions (cerebellum and hippocampus) raises intriguing questions about potential roles in neuroimmune communication and neuroinflammatory conditions that warrant further investigation .